Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
Quanterix Corporation (QTRX)
US:NASDAQ Investor Relations:
ir.quanterix.com/investor-relations
Company Research
Source: Business Wire
Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix’s ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the largest population-based assessment of Alzheimer’s Disease Neuropathological Changes (ADNC) to date, providing crucial, scalable data to redefine disease prevalence.The research, conducted on a Norwegian population-based cohort of over 11,000 individuals aged 58 and above, addresses a long-standing challenge in epidemiology: obtaining accurate ADNC prevalence data from a representative general population rather than smaller, clinic-based sample
Show less
Read more
Impact Snapshot
Event Time:
QTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTRX alerts
High impacting Quanterix Corporation news events
Weekly update
A roundup of the hottest topics
QTRX
News
- Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence [Yahoo! Finance]Yahoo! Finance
- Quanterix (NASDAQ:QTRX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $5.00 to $8.00. They now have a "hold" rating on the stock.MarketBeat
- Quanterix (NASDAQ:QTRX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=QTRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth [Yahoo! Finance]Yahoo! Finance
- Quanterix Announces Board and Leadership Changes to Support Next Stage of GrowthBusiness Wire
QTRX
Earnings
- 11/10/25 - Miss
QTRX
Analyst Actions
- 12/22/25 - Canaccord Genuity
QTRX
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/8/25 - Form 4
- QTRX's page on the SEC website